middle.news
How Trajan’s $166.5M Revenue Sets Up FY26 Growth Amid Volatility
1:47am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Trajan’s $166.5M Revenue Sets Up FY26 Growth Amid Volatility
1:47am on Saturday 30th of August, 2025 AEST
Key Points
7.4% revenue growth to $166.5 million in FY2025
nEBITDA improved to $15.5 million despite $3.9 million biotech syringe loss
Net debt reduced by 10.1% to $29.5 million; net debt to nEBITDA ratio under 2x
Growth driven across Capital Equipment, Components & Consumables, and Disruptive Technologies
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Trajan Group Holdings (ASX:TRJ)
OPEN ARTICLE